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Background: Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder in which leukemic cells
display a reciprocal t(9:22) chromosomal translocation that results in the formation of the chimeric BCR-ABL oncoprotein,
with a constitutive tyrosine kinase activity. Consequently, BCR-ABL causes increased proliferation, inhibition of apoptosis,
and altered adhesion of leukemic blasts to the bone marrow (BM) microenvironment. It has been well documented that
cancer cells can generate their own signals in order to sustain their growth and survival, and recent studies have revealed
the role of cancer-derived exosomes in activating signal transduction pathways involved in cancer cell proliferation.
Exosomes are small vesicles of 40–100 nm in diameter that are initially formed within the endosomal compartment,
and are secreted when a multivesicular body (MVB) fuses with the plasma membrane. These vesicles are released by
many cell types including cancer cells, and are considered messengers in intercellular communication. We have
previously shown that CML cells released exosomes able to affect the tumor microenvironment.
Results: CML cells, exposed up to one week, to exosomes showed a dose-dependent increased proliferation compared
with controls. Moreover, exosome treatment promotes the formation of LAMA84 colonies in methylcellulose. In a CML
xenograft model, treatment of mice with exosomes caused a greater increase in tumor size compared with controls
(PBS-treated mice). Real time PCR and Western Blot analysis showed, in both in vitro and in vivo samples, an increase in
mRNA and protein levels of anti-apoptotic molecules, such as BCL-w, BCL-xl, and survivin, and a reduction of the
pro-apoptotic molecules BAD, BAX and PUMA. We also found that TGF- β1 was enriched in CML-exosomes. Our
investigations showed that exosome-stimulated proliferation of leukemia cells, as well as the exosome-mediated
activation of an anti-apoptotic phenotype, can be inhibited by blocking TGF-β1 signaling.
Conclusions: CML-derived exosomes promote, through an autocrine mechanism, the proliferation and survival of
tumor cells, both in vitro and in vivo, by activating anti-apoptotic pathways. We propose that this mechanism is
activated by a ligand-receptor interaction between TGF-β1, found in CML-derived exosomes, and the TGF- β1
receptor in CML cells.
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Chronic myeloid leukemia (CML) is a clonal hematopoietic
stem cell disorder in which leukemic cells display a recip-
rocal t(9:22) chromosomal translocation that results in the
formation of the chimeric BCR-ABL oncoprotein, with a
constitutive tyrosine kinase activity [1,2]. Imatinib mesylate
(IM) is a selective and well-tolerated inhibitor of the BCR-
ABL tyrosine kinase, and has significantly improved the
prognosis of patients with chronic phase CML. Despite this
remarkable progress, a major problem associated with
the administration of imatinib is acquired resistance [3].
Therefore, there is an urgent need for new anticancer
agents and combinations that could improve responses
and survival rates for CML. Recently, a considerable
interest in the cancer field has focused on the role of the
microenvironment in regulating the growth, survival, and
drug-resistance of leukemic cells [4]. A variety of cyto-
kines, growth factors, adhesion molecules, and extracel-
lular matrix proteins are secreted by both tumor and
non-tumor cells, mediating cell-to-cell communication
within the tumor microenvironment, and providing a
suitable niche for cancer cell growth and survival. Re-
cently, exosomes have been considered as new vehicles
of these molecules into the tumor microenvironment
and, as a result, data is beginning to accumulate on
their role as new actors in the crosstalk between cancer
and normal cells in the tumor microenvironment. Exo-
somes are small vesicles of 40–100 nm in diameter that
are initially formed within the endosomal compartment,
and are secreted when a multivesicular body (MVB) fuses
with the plasma membrane [5]. We and other groups have
recently shown that cancer-derived exosomes modulate
the crosstalk between leukemia cells and the bone marrow
microenvironment [6,7]. In particular, we reported that
CML cells release exosomes, and that the addition of these
vesicles to vascular endothelial cells, as well as to bone
marrow stromal cells, affects in vitro and in vivo tumor
progression [6,8,9]. While increasing evidence is accumu-
lating on the role of exosomes in mediating paracrine in-
terplays within the tumor microenvironment, little is
known about their role in affecting the growth and sur-
vival of the releasing cells [10]. A regulated orchestration
of both survival and death pathways is essential for a var-
iety of normal biological processes, and disruptions of this
balance often lead to a cancer phenotype [11]. Therefore,
a better understanding of the molecular events that allow
tumors to evade apoptotic death should enable a more ra-
tional approach to anticancer drug design and therapy. To
the best of our knowledge, little is known about the role of
exosomes in influencing the balance between pro- and
anti- apoptotic pathways. A key regulator of the balance
between life and death is the transforming growth factor
β1 (TGF- β1), a multifunctional cytokine that regulates
growth, differentiation, apoptosis and migration of varioustypes of cells, including cancer cells [12]. Various studies
suggest that TGF-β1 activates PI3K/Akt/NF-kB/MMP9
signaling pathways in Philadelphia chromosome-positive
CML hemangioblasts [13-15]. Moreover, evidence suggests
that tumor exosomes express membrane-associated TGF-
β1 [16,17]. Here we show that LAMA84-derived exosomes
are able to promote, through an autocrine mechanism, the
proliferation and survival of tumor cells, both in vitro and
in vivo, by the activation of an anti-apoptotic pathway reg-
ulated by exosome-associated TGF- β1.Results
LAMA84-derived exosomes characterization
Exosomes from LAMA84 culture supernatant were isolated
and described by our group in 2012 [9]. Taverna et al. by
using scanning electron microscopy showed that CML vesi-
cles consisted of a homogenous membrane particles popu-
lation with an average diameter of 70 nm± 10. They also
showed that exosomes were positive for CD63 and Hsc70.
Here, we further characterized LAMA84-derived exo-
somes for the presence of other molecular markers, CD81,
Alix and Tsg101. Importantly, exosomes are negative for
Calnexin, an endoplasmic reticulum marker (Additional
file 1: Figure S1).LAMA84-derived exosomes promote in vitro and in vivo
tumor growth
In order to assess the ability of LAMA84-derived exosomes
to promote tumor growth, FBS-deprived LAMA84 cells
were treated for 48, 72, or 96 hours, or 1 week, with escalat-
ing doses of exosomes (5, 10 or 20 μg/ml). The BrdU prolif-
eration assay confirmed that at 72 hours of exosome
treatment there is an increase in the proliferation rate of
CML cells compared with untreated cells (Figure 1a). Simi-
lar data were obtained using MTT assay (data not shown).
To better evaluate the ability of CML-derived exosomes
to promote in vitro tumor growth, we performed a col-
ony formation assay in methylcellulose. As shown in
Figure 1b, LAMA84 cells treated with 1, 5, 10, 20 or
50 μg/ml of LAMA84-exosomes are able to form col-
onies in methylcellulose with a greater area than con-
trol cells.
The ability of CML exosomes to promote tumor growth
was also tested in an in vivo tumor xenograft model.
LAMA84 cells were inoculated subcutaneously in NOD/
SCID mice, and the mice were subsequently treated locally
twice a week with vehicle (PBS) or LAMA84-derived
exosomes. After 50 days, the mice were sacrificed, and
the tumors removed to measure tumor weight. Tumor
weight curve in Figure 1c shows that exosome-treated
mice developed larger tumors compared with control
mice.
Figure 1 CML-Derived Exosomes Promote in Vitro and in Vivo Tumor Growth. Cell growth was evaluated by BrdU assay (a). For the experiment
LAMA84 cells were incubated for 48, 72, or 96 hours, or 1 week, with increasing doses of LAMA84-exosomes (5–10–20 μg/ml). The values were plotted
as a percentage of the control (untreated cells); each point represents the mean ± SD for three independent experiments. (b) The addition of 1, 5, 10,
20 or 50 μg/ml of LAMA84 exosomes increased the area of CML colonies in methylcellulose compared with controls. Asterisks indicate a statistically
significant values in comparison to control (Ctrl) (*p≤ 0.05; **p≤ 0.01; *** p≤ 0.001). (c) LAMA84 cells were injected subcutaneously in NOD/SCID mice,
and mice were treated as described in Material and Methods. Comparison of the median tumor weight was used as an index of the proliferative
efficacy of CML-derived exosomes.
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pro- and anti-apoptotic molecules
To evaluate the mechanism by which CML-exosomes are
able to sustain tumor growth, we tested the expression of
different molecules involved in the apoptotic machinery.
As shown in Figure 2a, LAMA84 treated for 72, 96 hours,
or 1 week, with 5 or 10 μg/ml of LAMA84-derived exo-
somes showed a reduction of the pro-apoptotic genes
BAD, BAX and PUMA and an increase in mRNA levels
of the anti-apoptotic genes survivin, BCL-xl, and BCL-w.
Real-time PCR analysis of the mRNAs isolated from
in vivo xenograft tumors confirmed the data obtained
in vitro (Figure 2b), thus suggesting that tumor exosomes
are able to affect the balance between the pro- and anti-
apoptotic molecules. These results were confirmed with
Western blot analysis. Specifically, Figure 3a shows that in
exosome-treated LAMA84 cells there is the reduction of
BAD and BAX proteins, as well as an increase in the pro-
tein levels of BCL-xl, BCL-w, and survivin compared with
untreated cells after 72 or 96 hours of exosome treatment(10 μg/ml). Western blot analysis of in vivo samples
confirmed the in vitro data (Figure 3b). The decreased
expression of BAX, as well as the increased expression
of BCL-w, was also confirmed by immunohistochemical
analysis on tumor biopsies (Figure 3c).
CML-derived exosomes promote the activation of ERK, Akt
and NF-kB in LAMA84 treated cells
To determine which signaling pathways are responsible
for the activation of the pro-survival phenotype in
exosome-treated LAMA84 cells, we performed Western
blot analysis in the in vitro and in vivo samples. Since
the PI3/Akt or MAPK/ERK pathways are responsible for
the control of the growth and survival of cancer cells
[18,19], we wondered whether exosomes are able to in-
duce cancer cell proliferation through the activation of
these signaling pathways. As shown in Figure 4a, 10 μg/ml
of exosome treatment triggered a moderate phosphoryl-
ation of ERK after 72 hours of treatment. Moreover, after
96 hours of treatment, there was an increase in the
Figure 2 Anti-Apoptotic and Pro-Survival Effect of CML-Derived Exosomes on Gene Expression. (a) Real-time PCR analysis shows that
treatment of LAMA84 with LAMA84 exosomes up to 1 week increases the mRNA expression of the anti-apoptotic genes survivin, BCL-xl, and
BCL-w, while it decreases the mRNA levels of the pro-apoptotic genes BAD, BAX and PUMA. (b) Similar effects were observed in samples from
mice treated with exosomes compared with control mice, treated with PBS (black bar). Asteriks indicate a significant difference in comparison
to control (Ctrl) (**p ≤ 0.01; *** p ≤ 0.001).
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phosphorylation of ERK or Akt could be observed in
tumor biopsies from mice treated with exosomes com-
pared with control mice (Figure 4b). Exosome treat-
ment did not affect the total amount of these proteins.
NF-kB is one of the key proteins that regulate cancer
cell proliferation and survival by activating many pro-
survival and anti-apoptotic genes, such as BCL-xl and
survivin [20], as well as by interacting with other survival
pathways, such as PI3/Akt [21]. Therefore we examined
the level of this transcriptional factor. As shown in
Figure 4, exosome treatment induced a significant in-
crease in the level of NF-kB both in vitro and in vivo.
These data suggest that CML exosomes stimulate the
proliferation and survival of the producer cells via the
activation of ERK, Akt and NF-kB.TGF-β1 is expressed in LAMA84-exosomes and modulates
the SMAD pathway in CML cells
In order to investigate which molecule is present in
LAMA84 exosomes that could be responsible for the acti-
vation of pro-survival and proliferative pathways, we
assessed by Western blot the expression of TGF-β1 in
LAMA84-derived exosomes. As shown in Figure 5a (upper
panel), TGF-β1 is enriched in exosomes compared with
LAMA84 cells. Moreover, we observed that LAMA84 cells
express the TGF-β1 receptor (Figure 5a, lower panel). It is
well known that in cancer, the TGF-β1/TGF-β1 receptor
complex controls various downstream signaling pathways,
including Akt and MAPK signal transduction pathways, as
well as the canonical SMAD dependent pathway [22].
As shown in Figure 5b, the treatment of LAMA84 with
10 μg/ml of CML exosomes for 72 or 96 hours induces
Figure 3 Anti-Apoptotic and Pro-Survival Effect of CML-Derived Exosomes on Protein Expression. (a) Western blot analysis shows that
treatment of LAMA84 with 10 μg/ml of LAMA84 exosomes for 72 or 96 hours increases the expression of the anti-apoptotic molecules BCL-xl,
BCL-w, and survivin, while it decreases the expression of the pro-apoptotic molecules BAD and BAX. (b) Protein levels of the same molecules
were analyzed in the tumor biopsies of mice treated with exosomes (Exo 1 and Exo 2) and control mice treated with PBS (Ctrl 1 and Ctrl 2). Blots
were stripped and subsequently reprobed with an antibody against β -actin to ensure equal loading. (c) Representative photomicrographs showing
5-μm-thick paraffin-embedded sections of tumor biopsy specimens obtained from control mice (Ctrl) and exosome-treated mice (Exo) stained
for BAX and BCL-w.
Figure 4 CML Exosomes Trigger the in Vitro and in Vivo Activation of ERK/ Akt/ NF-Kb Pathways. (a) Western blot analysis shows that
treatment of LAMA84 with 10 μg/ml of LAMA84 exosomes for 72 or 96 hours triggers the phosphorylation of ERK and Akt without altering the
total level of these proteins, and increases the expression of NF-kB. (b) A comparable effect can be observed in CML xenografts treated or not
with exosomes.
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Figure 5 TGF-β1 Is Expressed on CML Exosomes. (a) Western blot analysis shows that LAMA84-derived exosomes express TGF- β1. Loading
was based on equal protein amount (upper panel). LAMA84 cells express TGF- β1 receptor (lower panel). (b) After 72 or 96 hours of treatment of
LAMA84 with 10 μg/ml of LAMA84-exosomes there is an increase in the phosphorylation of the downstream target of TGF-β1, SMAD 2/3; the
treatment does not alter the total level of the protein.
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total protein level. These data suggest that CML-derived
exosomes are able to establish an autocrine loop with their
producer cells, possibly through a ligand-receptor inter-
action mediated by exosome-associated TGF-β1.
Treatment of LAMA84 cells with TGF-β1 receptor inhibitor
blocks exosome-mediated effects
To further demonstrate the involvement of TGF-β1 signal-
ling pathway, we co-treated CML cells with exosomes and
TGF-β1 receptor inhibitor (SB). As shown in Figure 6a,
the addition of 10 or 20 μM of SB significantly reduced
the proliferation rate of exosome-treated cells and the size
of exosome-stimulated colony areas without affecting
the areas of control colonies (Figure 6b). Moreover the
co-treatment with 10 μM of SB was able to significantly
reduce exosome-stimulated increase of p-ERK and p-Akt
without affecting the total protein levels. In addition, SB
treatment reversed exosome-mediated activation of SMAD
2/3 (Figure 6c). In order to correlate the activation of TGF-
β1 dependent pathways with the exosome-mediated activa-
tion of an anti-apoptotic phenotype in LAMA84 cells, we
analyzed the levels of pro- and anti-apoptotic molecules in
LAMA84 co-treated with exosomes and SB. As shown in
Figure 6b the co-treatment with the inhibitor significantly
reversed exosome-mediated decrease of BAD and BAX, as
well as the increase of BCL-xl, BCL-w, and survivin. These
data provide evidence of the involvement of TGF-β1 in
exosome-mediated proliferation and survival of leukemic
cells.
Treatment of LAMA84 exosomes with TGF-β1 neutralizing
antibodies inhibits LAMA84 proliferation and colony
formation
In order to confirm the proliferative and pro-survival
effects of exosomal TGF-β1 on producer cells, we firstneutralized TGF β1 in LAMA84-derived exosomes, using
an anti-TGF-β1 antibody, and we then treated LAMA84
cells with these vesicles. As shown in Figure 7 the
stimulation of LAMA84 cells with TGF-β1 neutralizing
antibody- treated exosomes significantly reverses CML
cell proliferation induced by control exosomes (Figure 7a).
Furthermore, pretreated exosomes doesn’t alter the size of
LAMA84 colonies in methylcellulose (Figure 7b). Collect-
ively, these results indicate that exosomal TGF-β1 inter-
acts with TGF-β1 receptor on CML cells, leading to the
increase of cell proliferation and survival.
Discussion
We provide evidence that chronic myeloid leukemia-
derived exosomes enhance tumor growth and survival
through a direct autocrine effect. The autocrine stimulation
is of crucial importance for the growth and survival of
tumor cells, and may offer opportunities for treatment
of patients by targeting growth factors and their recep-
tors. Cancer cells are able to release nano-sized vesicles,
called exosomes, which modulate tumor behavior in
the surrounding microenvironment.
Exosomes are now considered an integral part of the
intercellular microenvironment, and may act as regula-
tors of cell-to-cell communication [5]. Increasing evidence
shows that these vesicles are able to induce phenotypic
changes in neighboring cells by activating specific cell
signaling pathways that lead to cancer progression. We
recently reported evidence of the paracrine mechanism
by which chronic myeloid leukemia-derived exosomes
promote cancer cell survival by inducing phenotypic
changes in endothelial and stromal cells [8,9]. Exosomes
can also act in an autocrine manner, acting on their pro-
ducer cells. Koga and colleagues have shown that breast-
cancer-derived exosomes stimulated the proliferation of
the parental cells [23]. A few years later, Qu and colleagues
Figure 6 Inhibition of TGF-β1 Receptor Signaling Reverses Exosome-Mediated Effects on CML Cells. (a) Cell growth was evaluated by BrdU
assay. LAMA84 cells were incubated for 72, 96 hours, or 1 week, with increasing doses of LAMA84-exosomes (10–20 μg/ml) plus 10 or 20 μM
of SB. The values were plotted as a percentage of the control (untreated cells); each point represents the mean ± SD of three independent
experiments. (b) Colony formation assay shows that the co-treatment of LAMA84 with 10 or 20 μg/ml of exosomes plus 10 or 20 μM of SB
reverses exosome-mediated increase of LAMA84 colonies area (** p ≤ 0.01; ***p ≤ 0.001). (c) Western blot analysis shows that treatment of
LAMA84 with 10 μg/ml of exosomes plus 10 μM of SB for 72 or 96 hours decreases the phosphorylation of ERK, Akt and SMAD 2/3 without
altering total protein level. The co-treatment with SB reverses exosome-mediated decrease of the pro-apoptotic molecules (BAD, BAX) as well
as the increase of the anti-apoptotic proteins (BCL-xl, BCL-w, survivin).
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cell proliferation, at least in part, by activation of PI3K/
Akt and mitogen-activated protein kinase/extracellular-
regulated protein kinase pathways [10]. Here, we show
that the promotion of proliferation and colony formation
of CML cell lines by CML-exosomes points to an import-
ant role of autocrine mechanisms mediated by these vesi-
cles in the biology of CML. The proliferative effect of
exosome stimulation was also confirmed in our in vivo
CML xenograft model, supporting the in vitro evidence.
The extracellular signal-regulated kinase (ERK) signaling
pathway is a major determinant in the control of diverse
cellular processes, such as proliferation and survival, and
together with the PI3K/Akt pathway is often up-regulated
in many cancers. Emerging evidence has shown that
tumor-derived exosomes are able to remodel the tumor
microenvironment by regulating these signaling pathwaysin target cells. Al-Nedawi and colleagues reported that
exosome-derived oncogenic EGFR from human squamous
cell carcinoma activated, in endothelial cells, MAPK and Akt
cell signaling pathways, promoting VEGF expression [24].
Furthermore, various studies of pancreatic- and colorectal-
derived exosomes have indicated a transfer of growth factor
encoding mRNA (VEGF, HGF, IL-8, CD44H) to tumor-
associated monocytes, leading to an anti-apoptotic response
due to the activation of the Akt pathway [25].
In our study, we correlate the in vitro and in vivo
exosome-mediated stimulation of CML growth and sur-
vival with a deregulated activation of both ERK and Akt
pathways. In particular, Western blot analysis showed an
increase in the phosphorylation of both kinases after exo-
some treatment. Our data on CML exosomes confirm what
Qu and collaborators previously described in exosome-
treated gastric cancer cell lines [10]. In addition to the
Figure 7 Exosomal TGF- β1 inhibition reverses exosome- mediated increase of proliferation and colonies area of LAMA84 cells. (a) Cell
growth was evaluated by BrdU assay. LAMA84 cells were incubated for 72, 96 hours, or 1 week, with LAMA84-exosomes (10–20 μg/ml) pretreated
or not with neutralizing anti TGF-β1 antibodies. The values were plotted as a percentage of the control (untreated cells); each point represents the
mean ± SD of three independent experiments. (b) Colony formation assay shows that the co-treatment of LAMA84 with 10 or 20 μg/ml of exosomes
pretreated with neutralizing anti TGF-β1 antibody reverses exosome-mediated increase of LAMA84 colonies area. Asterisks indicate a statistically
significant values (** p ≤ 0.01; ***p ≤ 0.001).
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exosome-treated cells an up-regulation of the anti-
apoptotic NF-kB signal transduction pathway, a down-
stream target of Akt. It is well known that Akt promotes
cells survival through the activation of NF-kB together
with the down-regulation of pro-apoptotic molecules and
the up-regulation of pro-survival molecules [26-28]. In
our in vitro and in vivo models, we found an increase in
the mRNA and protein levels of the pro-apoptotic mole-
cules BAD, BAX and PUMA, together with the increase of
the pro-survival molecules BCL-XL, BLC-w, and survivin.
Our data on the regulation of pro- and anti-apoptotic
molecules, together with the activation of ERK and Akt
pathways, suggest that CML exosomes trigger an anti-
apoptotic phenotype in the producer cells. Therefore, the
release of exosomes by CML cells could contribute to the
progression of leukemia through the triggering of an auto-
crine loop, thus representing a possible target for new
therapies.Among the molecules that act on cancer cells through
the establishment of an autocrine loop, TFG- β1 is a cru-
cial cytokine for CML progression. The transforming
growth factor 1 (TGF-β1) is a multifunctional cytokine
depending on cellular context. It is known for its cyto-
static effects in premalignant states and its pro-oncogenic
activity in advanced cancers. In additional to the canonical
SMAD pathway, TFG- β1 is able to regulate the so-called
non-SMAD signaling pathways, which include PI3K/Akt
and MAPKs, two key regulatory pathways of cancer cell
proliferation and survival [22]. Various studies have under-
lined the role of TGF-β1 in leukemia progression. Naka
and colleagues found that the TGF- β1 pathway is critical
in the maintenance of leukemia-initiating cells by control-
ling FOXO localization. Furthermore, studies have shown
that the combination of TGF-β inhibitors with imatinib ef-
ficiently depleted leukemia-initiating cells and retarded
CML development [15]. Furthermore, Zhu and colleagues
have shown that the BCR-ABL oncogene up-regulated
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kB/MMP9 signaling pathways. The TGF-β1-mediated
signaling led to an enhanced recruitment and mobilization
of leukemia stem cells to the peripheral circulation [13].
Here we add another piece of information on the role of
TGF-β1 in CML progression.
We found that TGF-β1 is enriched in LAMA84-
derived exosomes. Previous studies have reported the
presence of TGF-β1 in both cancer and non-cancer cells,
underscoring its role on exosome-stimulated effects on
recipient cells [16,29,30]. To further determine the auto-
crine involvement of exosomal-TGF-β1 in the stimulation
in leukemic cells, we used a commercially available TGF-
β1 receptor inhibitor or a specific neutralizing antibody to
exosomal TGF-β1. Our study showed that the exosome-
stimulated increase of cell proliferation, and the activation
of an anti-apoptotic phenotype can be inhibited by block-
ing TGF-β1 mediated pathways. Some studies have re-
ported that TGF-β1 levels are often elevated in human
tumors [31,32]. As a result of the wide variety of effects of
TGF-β1 on tumorigenesis, blocking the TGF-β pathway
may provide multiple therapeutic opportunities. There are
many TGF-β1 signaling antagonist agents under develop-
ment at both the pre-clinical and clinical stages [33]. Naka
and colleagues demonstrated that drug resistance. in
CML stem cells is due to TGF-β1 in the microenvir-
onment, and that the treatment of human CML stem
cells with a TGF-β1 inhibitor inhibited their clono-
genic activity in vitro [15]. Therefore, it is conceivable
that the anti-apoptotic effects of CML-derived exo-
somes on the producer cells may be partially due to
the presence of TGF-β1 on CML exosomes. Our data
underline the importance of evaluating the role of
leukemia-derived exosomes for the development of
combination therapies that potentiate the effects
of imatinib treatment.Figure 8 Working Hypothesis on Exosome-mediated Autocrine Loop.
cells through the establishment of an autocrine signaling loop mediated bConclusions
In summary, we have identified an autocrine role for
CML-derived exosomes that lead to the activation of
leukemia growth and survival (Figure 8). These data pro-
vide a new understanding of the role of exosomes in
cancer biology. The extensive autocrine stimulation that
occurs in tumors has significant implications for innova-
tive therapeutic and biomarker strategies for leukemia.
Methods
Ethics statement
All animal experiments were conducted in full compliance
with University of Palermo and Italian Legislation for Ani-
mal Care. The Dipartimento di Biopatologia e Biotecnologie
Mediche e Forensi (DiBiMef) Review Board approved this
study.
Cell culture and reagents
The human chronic myeloid leukemia cell line, LAMA84,
was obtained by DSMZ (Braunschweig, Germany) and
cultured in RPMI 1640 medium (Euroclone, UK),
supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 100 U/ml penicillin, and 100 μg/ml strepto-
mycin (Euroclone, UK). SB431542 (Cayman Chemical,
Michigan, USA) was solubilized at 10 mM stock solution
in DMSO, and stored at -20°C. Working dilutions were
prepared in medium. All other reagents were purchased
from Sigma-Aldrich (St. Louis, MO, USA), if not cited
otherwise.
Exosome preparation
Exosomes released by LAMA84 CML cells after a 24-
hour culture period in presence of FBS previously ultra-
centrifuged (vesicle free media) were isolated from
conditioned culture medium by differential centrifugation,
as previously described [6,8]. Briefly, culture medium wasCML derived exosomes promote proliferation and survival of leukemic
y exosome-associated TGF-β1.
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3,000 × g, 30 minutes at 10,000 × g and ultracentrifuged
90 min at 100,000 × g in a Type 70 Ti, fixed angle rotor.
Peletted exosomes were washed and then resuspended in
PBS. To further verify the identity of vesicles as exosomes,
we isolated exosomes on a 30% sucrose/D2O cushion.
Vesicles contained in the cushion were recovered, washed
several times, ultracentrifuged for 90 min in PBS and col-
lected for use. Exosome protein content was determined
with the Bradford assay (Pierce, Rockford, IL, USA). On
average, we recovered 10 micrograms of vesicles from
3×106 cells; this amount of exosomes was then used to
treat 1×106 cells.
Proliferation assay (BrdU assay)
Cell proliferation was assessed with a BrdU labeling ELISA
kit (Calbiochem, San Diego, CA, USA) according to
the manufacturer’s protocol. Briefly, LAMA84 cells
were seeded at a density of 0.1×106 in a 96-well plate
and exposed to escalating doses of LAMA84-exosomes
(5–10–20 μg/ml), pretreated or not with anti- TGF-β1
antibody, and in the presence or not of SB431542 (10,
20 μM) for up to one week. Twenty microliters of
BrdU were added to the cells 24 hours before each time
point. The absorbance was measured at dual wavelength
(450 nm and 540 nm). Means and standard deviations
generated from three independent experiments are
reported as the percentage of growth versus control
(untreated cells). Cell proliferation curves were derived
from these data with Microsoft Excel software.
Colony formation assay
LAMA84 cells were plated in 6-well (2000 cells/ml/well)
in Iscove’s-methylcellulose medium (Methocult H4230,
Stem Cell Technologies, Vancouver, Canada) containing
or not LAMA-derived exosomes (1, 5, 10, 20, 50 μg/ml),
pretreated or not with anti- TGF-β1 antibodies, and in
the presence or not of SB431542 (10, 20 μM). After
14 days of culture, LAMA84 colonies were observed by
phase-contrast microscopy and photographed. The area
of twenty LAMA84 colonies per condition was measured
with the IMAGE-J software (http://rsbweb.nih.gov/ij/).
CML mouse xenograft
Male NOD/SCID mice, four-to-five weeks old, were pur-
chased from Charles River (Charles River Laboratories
International, Inc, MA, USA) and acclimated for a week
prior to experimentation. Mice received filtered water
and sterilized diet ad libitum. Animals were observed
daily and clinical signs were noted. Mice were randomly
assigned to two groups of seven. Each mouse was inocu-
lated subcutaneously in the right flank with viable single
human LAMA84 cells (2 × 107) suspended in 0.2 ml
of PBS with: (i) PBS (vehicle) or (ii) LAMA84-derivedexosomes (100 μg/mouse). The day of injection was
considered Day 0. Treatments with PBS (control group) or
exosomes were repeated twice a week, in the tumor site.
Xenograft tumors were measured and mice were weighed
twice a week. Tumor volume was determined by calliper
with the following formula: LxW2/2 =mm3 where L and
W are the longest and shortest perpendicular measure-
ments in millimeters, respectively. The same formula was
used to calculate tumor weights assuming that 1 mm3 =
1 mg. Animals were euthanized at day 50, the tumor
resected, and the tumor weights measured. Xenografts
were resuspended in RNA later for further RNA isolation
in 4% formaldehyde for immunohistochemical analysis or
maintained dried at -80°C for protein isolation.
RNA extraction and real-time PCR
LAMA84 were grown in 12-well plates and treated with
5 or 10 μg/ml of LAMA84- exosomes for 72, 96 hours,
or 1 week. Tumor biopsies soon after removal were
stored in RNAlater solution (Applied Biosystems, Foster
City, California, USA). Each sample was lysed in a tissue
homogenizer. RNA was extracted using the commercially
available Illustra RNAspin Mini Isolation Kit (GE Health-
care, Little Chalfont, Buckinghamshire, UK), according
to manufacturer’s instructions. Total RNA was reverse-
transcribed to cDNA using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystem). RT-QPCR
was performed in 48-well plates using the Step-One Real-
Time PCR system (Applied Biosystem).
For quantitative SYBER®Green realtime PCR, reactions
were carried out in a total volume of 20 μl containing
2× SYBR®Green I Master Mix (Applied Biosystems), 2 μl
















All obtained from Invitrogen (Foster City, CA, USA).
Real-time PCR was performed in duplicates for each data
point. Relative changes in gene expression between con-
trol and treated samples were determined with the ΔΔCt
method. Levels of the target transcript were normalized to
a GAPDH endogenous control, constantly expressed in all
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were made between treated samples and control ΔCt
values. Final values were expressed as fold of induction.
Western blot
LAMA84 cells were treated or not for 72 or 96 hours
with 10 μg/ml of LAMA84-derived exosomes in the
presence or not of 10 μM SB431542.Total protein cell
lysates or exosome lysates were obtained and analyzed
by SDS-PAGE in reducing- or non-reducing conditions
followed by Western blotting, as previously described
[6]. Antibodies used in the experiments were anti-Akt,
phospho-Akt, Erk 1/2, phospho Erk 1/2, NF-kB, SMAD
2/3, phospho SMAD 2/3, β-actin, Alix (all from Cell
Signalling Technology, MA, USA), anti-BAD, BAX, BCL-
xL, BCL-w, survivin, TGF-β1, TGF- β1 receptor, Tsg101,
CD81, CD63, Hsc70 and Calnexin (all from Santa Cruz
Biotechnology, CA, USA).
Immunohistochemical staining
Mice xenografts were immediately fixed with 4% formal-
dehyde and embedded in paraffin. IHC for BAX and
BCL-w was performed on 5-μm-thick paraffin-embedded
sections from tumor biopsies from mice treated with exo-
somes or with PBS (control). Isotype-matched irrelevant
antibodies were used as a negative control. Following
rehydration, the antigen was unmasked for 45 minutes
in a 95°C microwave with Dako Target Retrieval Solution
(pH 6; Dako, Carpinteria, California, USA). Endogenous
peroxidase was blocked for 10 minutes with Dako perox-
idase blocking reagent, and non-specific binding was
blocked for 20 minutes with Dako protein block. The
primary antibodies anti-human BAX and BCL-w (1:100
diluition, Santa Cruz Biotechnology) were added and
incubated for 1 hour at room temperature. For control
staining, primary antibodies were replaced with irrele-
vant isotype-matched antibodies (AbCam, Cambridge, UK).
The slides were then incubated for 30 minutes with
peroxidise-conjugated Dako EnVision polymer, and per-
oxidase activity was visualized with diaminobenzidine
chromogen (Dako). Slides were lightly counterstained
with hematoxylin before dehydration and mounting in
DePex (VWR International, Oslo, Norway).
TGF-β neutralization
Exosomes were incubated with TGF-β1 neutralizing anti-
body (20 mg/mL, Abcam, Cambridge, UK) for 2 hours at
37°C. LAMA84 cells were treated as indicated in results
and figure legends.
Statistical analysis
Data are expressed as means ± SD of three independent
experiments. Statistical analysis was done with a pairedsample t-test. Differences were considered significant
when p ≤ 0.05.
Additional file
Additional file 1: Figure S1. LAMA84 cells-Derived Exosomes
characterization. (a) Ponceau staining of LAMA84 cell lysates and exosomes.
(b) Detection of Calnexin, CD81, Alix, Tsg10, Hsc 70 and CD63 in 30 μg of
cell and exosomes lysates. Exosomes are positive for CD81, Alix, Tsg101,
Hsc70 and CD63 but negative for the endoplasmic reticulum protein,
Calnexin.
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